CISATRACURIUM BESYLATE

N/A

Manufactured by Fresenius Kabi USA, LLC

3,661 FDA adverse event reports analyzed

Last updated: 2026-04-15

About CISATRACURIUM BESYLATE

CISATRACURIUM BESYLATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for CISATRACURIUM BESYLATE include OFF LABEL USE, HYPOTENSION, ANAPHYLACTIC SHOCK, ANAESTHETIC COMPLICATION NEUROLOGICAL, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CISATRACURIUM BESYLATE.

Top Adverse Reactions

OFF LABEL USE156 reports
HYPOTENSION146 reports
ANAPHYLACTIC SHOCK116 reports
ANAESTHETIC COMPLICATION NEUROLOGICAL115 reports
DRUG INEFFECTIVE113 reports
DRUG INTERACTION113 reports
ANAPHYLACTIC REACTION112 reports
RHABDOMYOLYSIS83 reports
CARDIAC ARREST82 reports
ACUTE KIDNEY INJURY74 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS72 reports
HYPOXIA68 reports
BRADYCARDIA66 reports
TACHYCARDIA66 reports
RESPIRATORY FAILURE60 reports
METABOLIC ACIDOSIS56 reports
HYPERTHERMIA MALIGNANT54 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME52 reports
PYREXIA52 reports
SEROTONIN SYNDROME52 reports
SEPTIC SHOCK45 reports
DYSPNOEA41 reports
HYPERTENSION41 reports
PNEUMONIA40 reports
ACUTE RESPIRATORY DISTRESS SYNDROME37 reports
PRODUCT USE IN UNAPPROVED INDICATION37 reports
COMA36 reports
COVID 1936 reports
MYOCLONUS36 reports
TOXICITY TO VARIOUS AGENTS36 reports
THROMBOCYTOPENIA34 reports
MIXED LIVER INJURY33 reports
RENAL FAILURE33 reports
BRONCHOSPASM32 reports
CONDITION AGGRAVATED32 reports
SHOCK32 reports
BLOOD CREATININE INCREASED31 reports
CARDIO RESPIRATORY ARREST30 reports
CYANOSIS30 reports
DEATH30 reports
SEPSIS30 reports
VOMITING30 reports
CIRCULATORY COLLAPSE29 reports
DELIRIUM29 reports
OXYGEN SATURATION DECREASED29 reports
BLOOD PRESSURE DECREASED27 reports
TOXIC EPIDERMAL NECROLYSIS27 reports
CARDIOGENIC SHOCK26 reports
HYPOKALAEMIA26 reports
RESPIRATORY DEPRESSION26 reports
VENTRICULAR FIBRILLATION26 reports
ERYTHEMA25 reports
HYPERKALAEMIA24 reports
NERVOUS SYSTEM DISORDER24 reports
HYPERTRANSAMINASAEMIA23 reports
MATERNAL EXPOSURE DURING PREGNANCY23 reports
RASH23 reports
RENAL IMPAIRMENT23 reports
ANAEMIA22 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION22 reports
HYPERTHERMIA22 reports
KLEBSIELLA INFECTION22 reports
URTICARIA22 reports
ENCEPHALOPATHY21 reports
NAUSEA21 reports
SINUS TACHYCARDIA21 reports
ASPARTATE AMINOTRANSFERASE INCREASED20 reports
FOETAL EXPOSURE DURING PREGNANCY20 reports
HAEMODYNAMIC INSTABILITY20 reports
NEUROLEPTIC MALIGNANT SYNDROME20 reports
ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS19 reports
APNOEA19 reports
DEPRESSED LEVEL OF CONSCIOUSNESS19 reports
DRUG HYPERSENSITIVITY19 reports
ELECTROCARDIOGRAM QT PROLONGED19 reports
HEPATOCELLULAR INJURY19 reports
OVERDOSE19 reports
PAIN19 reports
PRURITUS19 reports
ACIDOSIS18 reports
AGITATION18 reports
ALTERED STATE OF CONSCIOUSNESS18 reports
CONSTIPATION18 reports
COVID 19 PNEUMONIA18 reports
POST PROCEDURAL COMPLICATION18 reports
PULSELESS ELECTRICAL ACTIVITY18 reports
ACUTE RESPIRATORY FAILURE17 reports
BRAIN OEDEMA17 reports
DIZZINESS17 reports
HEART RATE INCREASED17 reports
PROPOFOL INFUSION SYNDROME17 reports
PULMONARY EMBOLISM17 reports
PULMONARY OEDEMA17 reports
BLOOD PRESSURE INCREASED16 reports
EOSINOPHILIA16 reports
HYPONATRAEMIA16 reports
LUNG DISORDER16 reports
PSEUDOMONAL SEPSIS16 reports
RESPIRATORY DISTRESS16 reports
TREMOR16 reports

Report Outcomes

Out of 2,110 classified reports for CISATRACURIUM BESYLATE:

Serious 96.6%Non-Serious 3.4%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male1,057 (55.5%)
Female837 (44.0%)
Unknown9 (0.5%)

Reports by Age

Age 6775 reports
Age 6256 reports
Age 5154 reports
Age 6049 reports
Age 4048 reports
Age 6448 reports
Age 5345 reports
Age 6342 reports
Age 5839 reports
Age 5737 reports
Age 4735 reports
Age 5935 reports
Age 6134 reports
Age 6534 reports
Age 6833 reports
Age 5530 reports
Age 4127 reports
Age 4827 reports
Age 5027 reports
Age 6627 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CISATRACURIUM BESYLATE?

This profile reflects 3,661 FDA FAERS reports that mention CISATRACURIUM BESYLATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CISATRACURIUM BESYLATE?

Frequently reported terms in FAERS include OFF LABEL USE, HYPOTENSION, ANAPHYLACTIC SHOCK, ANAESTHETIC COMPLICATION NEUROLOGICAL, DRUG INEFFECTIVE, DRUG INTERACTION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CISATRACURIUM BESYLATE?

Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with CISATRACURIUM BESYLATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.